




UNIVERSITY OF HAWAI'I  
CANCER CENTER

TRANSLATIONAL AND CLINICAL RESEARCH PROGRAM  
DISTINGUISHED LECTURER SERIES SEMINAR

***"Did we learn anything by targeting  
the IGF receptor?"***



**Dr. Douglas Yee, MD**  
**Director, Masonic Cancer Center**  
**Professor, Dept. of Medicine/Hematology, Oncology, and**  
**Transplantation; Professor, Dept. of Pharmacology, School**  
**of Medicine, University of Minnesota, Minneapolis MN**

Friday, November 9, 2018  
12:00 Noon to 1:00 PM, Sullivan Conference Center  
University of Hawaii Cancer Center

*Light refreshments will be served, following the seminar.*

## CURRICULUM VITAE

Douglas Yee, M.D.

- Office Address: Masonic Cancer Center  
University of Minnesota  
Mayo Mail Code 806  
420 Delaware St. SE  
Minneapolis, MN 55455  
Telephone: (612) 626-8487; FAX: (612) 626-3069  
E-mail: yeexx006@umn.edu
- Education:
- 1977 B.S. With high distinction--Anthropology and Zoology  
University of Michigan, Ann Arbor, MI
- 1981 M.D. University of Chicago, Pritzker School of Medicine  
Chicago, IL
- Positions Held:
- 1981-1984 Medical Intern and Resident, North Carolina Memorial Hospital  
University of North Carolina, Chapel Hill, NC
- 1984-1985 Chief Medical Resident, North Carolina Memorial Hospital  
University of North Carolina, Chapel Hill, NC
- 1985-1988 Medical Staff Fellow, Medicine Branch  
National Cancer Institute, Bethesda, MD
- 1988-1989 Instructor, Department of Medicine  
Georgetown University Medical Center, Washington DC
- 1989-1993 Assistant Professor, Department of Medicine/Medical Oncology  
University of Texas Health Science Center, San Antonio, TX
- 1993-1999 Associate Professor, Department of Medicine/Medical Oncology,  
University of Texas Health Science Center, San Antonio, TX
- 1999-present Professor, Department of Medicine/Hematology, Oncology, and  
Transplantation  
Professor, Department of Pharmacology  
School of Medicine, University of Minnesota, Minneapolis, MN

1999-2009 Tickle Family Land Grant Chair in Breast Cancer Research  
Masonic Cancer Center, University of Minnesota, Minneapolis, MN

2007-present Director, Masonic Cancer Center, University of Minnesota

2008-present John H. Kersey Chair in Cancer Research

Board Certification:

September 12, 1984--Diplomate, Internal Medicine, American Board of Internal Medicine  
November 10, 1987--Diplomate, Medical Oncology, American Board of Internal Medicine

License:

August 1984--Permanent North Carolina State License No. 28390  
September 1988--District of Columbia License No. 17640  
August 1989--Texas License No. H6991  
May 1999—Minnesota License No. 41547

Awards and Honors:

1977--Phi Beta Kappa  
1981--Pritzker School of Medicine, Catherine Dobson Award--Best oral presentation of research  
by a non-Ph.D. student  
1990--Pew Scholar in the Biomedical Sciences  
1992--Research Career Development Award KO4-CA01670  
2010 – Komen for the Cure Scholar

Other Professional Activities:

1992-1999 Program Leader, Growth Factor Program, San Antonio Cancer Institute  
2/94,10/95 Study Section Member, Endocrinology 1 – Breast Cancer, USAMRMC  
2/95-6/98 Member, Metabolic Pathology Study Section, NIH  
10/95, 10/96 Reviewer, Breast Cancer Research Review Committee, Commonwealth of  
Massachusetts  
10/96 Study Section member, Endocrinology 3, USAMRMC  
4/97 Reviewer, Scientific Review Group, Subcommittee C, Basic and Preclinical  
Sciences  
4/97, 4/98, 4/99 Study Section Member, Basic Breast Biology, California Breast Cancer Research  
Program, San Francisco, CA  
4/00 Reviewer, RAID IV, NIH/Developmental Therapeutics Program, Fredericksburg,  
MD  
4/01, 4/02, 4/03 Study Section Member, Etiology and Prevention, California Breast Cancer  
Research Program, San Francisco, CA  
9/97, 9/98, 9/99 Study Section Member, Endocrinology 1 – Breast Cancer, USAMRMC  
11/99-present Program Leader, Breast Cancer Program, University of Minnesota Cancer Center  
2000-2004 Chair, Endocrinology 2 – Breast Cancer Study Section, USAMRMC  
2000-2004 Member, Subcommittee F, Manpower and Training Subcommittee, NIH/NCI

8/01, 8/02	Study Section Member, National Health Research Initiative, Taiwan
10/02	Chair, Clinical Translational Research and Biotech Study Section, USAMRMC
6/02-present	Member, MICaB Ph.D. Training Program
2003-2004	ASCO Program Committee, Tumor Biology
2004-2011	External Scientific Advisory Panel – NSABP Tissue Utilization Committee
2004-2008	Scientific Advisory Board – Singapore Cancer Syndicate
2004-2006	Ad Hoc Member, Cancer Biomarkers Study Section, NIH/NCI
2004-present	External Advisory Board – Vanderbilt SPORE in Breast Cancer
2006	Track Leader, ASCO Breast Cancer Education Committee
2006-2015	Board Member, Susan G. Komen Minnesota
1/07	Study Section Member, Special Emphasis Panel, Cellular and Tissue Biology Cluster, NIH/NCI
1/07-6/10	Study Section Member, Cancer Biomarkers Study Section, NIH/NCI
9/07-7/2013	Data Monitoring Committee, NSABP
9/07-present	American College of Radiology Intervention Network Experimental Imaging Sciences Committee
1/08	Chair, Molecular & Cellular Biology & Genetics Study Section, Susan G. Komen for the Cure
3/08	Member, Promise Grant Study Section, Susan G. Komen for the Cure
5/08, 2/09	Ad hoc member, Integration Panel, Breast Cancer Research Program, U.S. Army Medical Research and Materiel Command
7/08	Program Committee, CTRC-AACR San Antonio Breast Cancer Symposium
7/08	Chair, Fellowship Award Committee, CTRC-AACR San Antonio Breast Cancer Symposium
7/08-present	Member, I-SPY2 Executive Operations Committee
7/08-present	Co-chair, I-SPY2 Agents Committee
11/08-present	Scientific Advisory Committee, Army of Women, Dr. Susan Love Research Foundation – Avon Foundation
11/08-11/11	Finance Committee Member, AACR
11/08	Scientist Reviewer, Targeted Therapies 2 Study Section, Komen for the Cure
3/09, 3/10	Reviewer, ASCO Advanced Clinical Research Award
4/10-present	External Advisory Board, Cancer Therapy and Research Center, San Antonio
6/10-6/12	Member, NCI Subcommittee A – Cancer Center Parent Committee
7/10-present	Komen Scholar (Scientific Advisory Council), Komen for the Cure
7/10	Scientific Review Committee, 2010 BCRF-AACR Grants for Translational Breast Cancer Research
3/11	Chair, Scientific Program Committee, 2013 ASCO Annual Meeting
12/11-present	External Advisory Board, Dan L. Duncan Cancer Center, Baylor College of Medicine
12/11-present	External Advisory Board, University of Cincinnati Cancer Center
2/12-7/16,	
2/16-present	Program Planning Committee, San Antonio Breast Cancer Symposium
1/12	Co-chairperson, AACR Special Conference on <i>Advances in Breast Cancer Research; Genetics, Biology, and Clinical Applications</i>
10/12-present	Member, I-SPY2 Data Access and Publications Committee

10/13 Chairperson, Cancer Prevention and Treatment, Special Study Section ZRG  
OTC-B

1/14 External Advisor, Cell Signaling program, University of Wisconsin Carbone  
Cancer Center

4/14-present Member, AACR Scientific Policy and Governmental Affairs Committee

5/15 Study Section member, California Breast Cancer Research Program

5/15 Programmatic Reviewer, Breast Cancer Research Program, Department of  
Defense, Congressionally Directed Medical Research Program

5/15-present External Advisor, University of Nebraska The Fred & Pamela Buffett Cancer  
Center

10/15-present External Advisor, University of Wisconsin Carbone Cancer Center

11/15 Planning Committee, Research with Human Participants: The National Debates,  
University of Minnesota

11/16-present External Advisor, University of Maryland Greenebaum Cancer Center

4/16, 4/17 Chair, California Breast Cancer Research Program Clinical, Prevention &  
Biological Sciences Review Committee

7/17 Reviewer, ZCA-1 RTRB-E, NCI, PDX Development and Trial Centers

10/17 Ad hoc reviewer, Subcommittee F – Institutional Training and Education

10/17 Ad hoc reviewer, Subcommittee A – Cancer Centers

#### Editorial Boards

1992-present *Breast Cancer Research and Treatment*

2000-present *Journal of Mammary Gland Biology and Neoplasia*

2004-present *Heme/Onc Today*

2008-2013 *Journal of Clinical Oncology*

2008-2014 *Cancer Prevention Research*

2009-2013 *Endocrinology*

2009-2014 *Hormones and Cancer*

2014-present Senior editor, *Clinical Cancer Research*

Scientific Editor: *Journal of the National Cancer Institute Monographs*, Vol 10, 1990.  
*Breast Cancer Research and Treatment*, Vol 22, 1992  
*Breast Cancer Research and Treatment*, Vol 47, 1998  
*Journal of Mammary Gland Biology and Neoplasia*, Vol 51, 1999  
*Breast Diseases*, 2003  
*Journal of Mammary Gland Biology and Neoplasia*, 2008

### Peer-Reviewed Publications

1. Given D, Yee D, Griem K, Kieff K. DNA of Epstein-Barr virus V. Direct repeats of the ends of Epstein-Barr virus DNA. *J Virology* 30:852-862, 1979.
2. Yee D, Cullen KJ, Paik S, Perdue J, Hampton B, Schwartz A, Lippman ME, Rosen N. Insulin-like growth factor II mRNA expression in human breast cancer. *Cancer Res* 48:6691-6696, 1988.
3. Cullen KJ, Yee D, Bates SE, Brunner N, Clarke R, Dickson RB, Huff KK, Paik S, Rosen N, Valverius E, Zugmaier G, Lippman ME. Regulation of human breast cancer by secreted growth factors. *Acta Oncologica* 28:835-839, 1989.
4. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N. Analysis of IGF-I gene expression in malignancy, evidence for a paracrine role in human breast cancer. *Mol Endocrinol* 3:509-517, 1989.
5. Yee D, Favoni RE, Lupu R, Cullen KJ, Lebovic GS, Huff KK, Lee PDK, Lee YL, Powell DR, Dickson RB, Rosen N, Lippman ME. The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells. *Biochem Biophys Res Commun* 158:38-44, 1989.
6. Veillette A, O'Shaughnessy J, Horak ID, Israel MA, Yee D, Rosen N, Fujita DJ, Tanaka A, Biedler JL, Bolen JB. Coordinate alteration of pp60 c-src abundance and c-src RNA expression in human neuroblastoma variants. *Oncogene* 4:421-427, 1989.
7. Paik S, Rosen N, Chung W, You JM, Lippman ME, Perdue JF, Yee D. Blastemal cells are the main source of IGF-II mRNA in fetal kidney and Wilms' tumor. *Lab Invest* 61:522-526, 1989.
8. Yee D, Lebovic GS, Marcus RR, Rosen N. Identification of an alternative type I IGF receptor beta chain mRNA transcript. *J Biol Chem* 264:21439-21441, 1989.
9. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N. Insulin-like growth factor receptor expression and function in human breast cancer. *Cancer Res* 50:48-53, 1990.
10. Lippman ME and Yee D. Introduction. *J Natl Cancer Inst Monogr* 10:1, 1990.
11. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell D, Reynolds CP, Rosen N. IGF-I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation: A potential autocrine growth factor. *J Clin Invest* 86:1806-1814, 1990.
12. Tobin G, Yee D, Brunner N, Rotwein P. A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. *Mol Endocrinol* 4:1914-1920, 1990.

13. Cullen KJ, Yee D, Rosen N. Insulin-like growth factors in human malignancy. *Cancer Invest* 9:443-454, 1991.
14. Yee D, Favoni RE, Lippman ME, Powell DR. Identification of insulin-like growth factor binding proteins in breast cancer cells. *Breast Cancer Res Treat* 18:3-10, 1991.
15. Reddy KB, Yee D, Osborne CK. Rapid identification of transfected plasmid vectors in cells by PCR. *BioTechniques* 10:481-483, 1991.
16. Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of IGF-I, its binding protein, and its receptor in ovarian cancer. *Cancer Res* 51:5107-5112, 1991.
17. Martin DM, Yee D, Feldman EL. Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. *Mol Brain Res* 12:181-186, 1992.
18. McGuire WL Jr, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D. Regulation of insulin-like growth factor binding protein expression by breast cancer cells; use of IGFBP-1 as an inhibitor of IGF action. *J Natl Cancer Inst* 84:1336-1341, 1992.
19. Martin DM, Yee D, Carlson RO, Feldman EL. Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. *Mol Brain Res* 5: 241-246, 1992.
20. Figueroa JA, Yee D, McGuire WL. Prognostic indicators in early breast cancer. *Am J Med Sci* 305:176-182, 1993.
21. Brüner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen RJ. Effect of endocrine therapy on growth of the human breast cancer xenograft is directly correlated with a specific downregulation of IGF-II. *Eur J Cancer* 29A:562-569, 1993.
22. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. *J Cell Biochem* 52:196-205, 1993.
23. Randolph AE, Yee D, Feldman EL. Insulin-like growth factor binding protein expression in human retinal pigment epithelial cells. *Ann NY Acad Sci* 692:265-267, 1993.
24. Feldman EL, Randolph AE, Yee D. Insulin-like growth factor binding protein expression in SH-SY5Y neuroblastoma cells. *Ann NY Acad Sci* 692:262-264, 1993.
25. Sarosdy MF, Hutzler DH, Yee D, Von Hoff DD. *In vitro* sensitivity testing of human bladder cancers and cell lines to TP-40: a hybrid protein with selective targeting and cytotoxicity. *J Urol* 150:1950-1955, 1993.

26. Noravud N, Lippman SM, Weber RS, Rodriguez GI, Yee D, Dimery IW, Von Hoff DD, Hong WK. Phase II trial of 13-cis-retinoic acid and interferon-alpha 2a in recurrent head and neck cancer. *Invest New Drugs* 11:57-60, 1993.
27. Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D. Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. *Eur J Cancer* 29A:2015-2019, 1993.
28. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum and estrogen dependent growth of MCF-7 human breast cancer cells. *J Cell Physiol* 157:229-236, 1993.
29. McGuire SE, Hilsenbeck SG, Figueroa JA, Yee D. Detection of insulin-like growth factor binding proteins in breast cancer by ligand blotting. *Cancer Letters* 72:25-32, 1994.
30. Yee D, Jackson JG, Kozelsky TW, Figueroa JA. Insulin-like growth factor binding protein-1 (IGFBP-1) expression inhibits IGF-1 action in MCF-7 breast cancer cells. *Cell Growth Differ* 5:73-77, 1994.
31. Yee D, Jackson JG, Von Hoff DD, Ravdin PM. Use of insulin-like growth factor I expression to distinguish between breast and ovarian cancer: Report of a case. *Am J Med Sci* 307:108-111, 1994.
32. Yee D, Sharma J, Hilsenbeck SG. Prognostic significance of insulin-like growth factor binding protein expression in axillary lymph node-negative breast cancer. *J Natl Cancer Inst* 86:1785-1788, 1994.
33. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor- $\alpha$  expression. *Cell Growth Differ* 5:1275-1282, 1994.
34. Grellier P, Yee D, Gonzalez M, Abboud SL. Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP-4 in bone marrow stromal cells. *Br J Haematol* 90:249-257, 1995.
35. Figueroa JA, Lee AV, Jackson JG, Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor binding protein-1: Evidence for an IGF-II autocrine growth loop. *J Clin Endocrinol Metab* 80:3476-3482, 1995.
36. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Insulin-like growth factor binding protein-3 (IGFBP-3) mRNA and protein expression are correlated in primary breast cancer tissues: Higher levels are detected in tumors with poor prognostic features. *J Natl Cancer Inst* 88:601-606, 1996.



37. Cheng H-L, Randolph A, Yee D, Delafontaine P, Tennekoon G, Feldman EL. Characterization of insulin-like growth factor-I (IGF-I), IGF-I receptor and binding proteins in transfected nerves and cultured Schwann cells. *J Neurochemistry* 66:525-536, 1996.
38. Yee D, Van Den Berg C, Kozelsky TW, Kuhn JG, Cox GN. Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice. *Biomed Pharmacother* 59:154-157, 1996.
39. Grellier P, Sabbah M, Fouqueray B, Woodruff K, Yee D, Abboud HE, Abboud SL. Characterization of insulin-like growth factor binding proteins and regulation of IGFBP-3 in human mesangial cells. *Kidney International* 49:1071-1078, 1996.
40. Grellier P, Feliers D, Yee D, Woodruff K, Abboud SL. Interaction between insulin-like growth factor-I and insulin-like growth factor-binding proteins in TC-1 stromal cells. *J Endocrinol* 149:519-529, 1996.
41. Yee D, McGuire SE, Br nner N, Kozelsky TW, Allred DC, Chen S-H, Woo S LC. Adenoviral mediated gene transfer of Herpes Simplex Virus thymidine kinase (HSVtk) in an ascites model of human breast cancer. *Human Gene Therapy* 7:1251-1257, 1996.
42. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng CN, Lee AV, Yee D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. *Clin Cancer Res* 3:103-109, 1997.
43. Van Den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng C-N, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. *Eur J Cancer* 33:1108-1113, 1997.
44. Lee AV, Weng C-N, Jackson JG, Yee D. Activation of estrogen-mediated gene transcription by insulin-like growth factor-1 (IGF-1) in human breast cancer cells. *J Endocrinol* 152:39-47, 1997.
45. Lee AV, Weng C-N, McGuire SE, Wolf DM, Yee D. Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor. *Biotechniques* 23:1062-1068, 1997.
46. Dong Q, Du H, Farris S, Kolakowski LF Jr, Lee AV, Mandarino LJ, Fan JB, Yee D, Liu F: Chromosome localization, expression and characterization of an src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10g. *J Biol Chem* 272:29014-29112, 1997.
47. Favoni RE, de Cupis A, Bruno S, Yee D, Ferrera A, Pirani P, Costa A, Decensi A. Modulation of the insulin-like growth factor-1 system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. *Br J Cancer* 77:2138-2147, 1998.

48. Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor positive human breast cancer cells. *J Biol Chem* 273:9994-10003, 1998.
49. Lee AV, Jackson JG, Gooch JG, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of the insulin-like growth factor pathway by estrogen in human breast cancer cells. *Mol Endocrinol*, 13:787-796, 1999.
50. Gooch JL, Lee AV, Yee D. Interleukin-4 induces growth inhibition and apoptosis in human breast cancer cells. *Cancer Res* 58:4199-4205, 1998.
51. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects. *Breast Cancer Res Treat*, 56:1-10, 1999.
52. Gooch JL, Herrera RE, Yee D. The role of p21 in IFN $\gamma$ -mediated growth inhibition of human breast cancer cells. *Cell Growth Differ*, 11:335-342, 2000
53. Jackson JG, Yee D. IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. *Growth Hormone & IGF Research*, 9:280-289, 1999.
54. Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, Powell DR. FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. *Endocrinology* 140:3140-3146, 1999
55. Gooch JL, Yee D. Strain specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. *Cancer Lett* 144:31-37, 1999
56. Jackson JG, Yoneda T, Clark GM, Yee D. Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. *Clin Cancer Res* 6:1135-1139, 2000
57. Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG. Phosphorylation and nuclear exclusion of the forkhead transcription factor fkhr after epidermal growth factor treatment in human breast cancer cells. *Oncogene*.19:4574-4581, 2000
58. Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D. IGF-I induced degradation of insulin receptor substrate-1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition. *Mol Cell Biol* , 20:1489-1496, 2000
59. Patil R, Chavez JB, Yee D. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells, *Breast Cancer Res Treat*, 62:109-115, 2000

60. Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate- 2 (IRS-2) in metastatic variants of human breast cancer cell lines. *Oncogene* 20:7318-7325. 2001
61. Gooch JL, Lee AV, Christy BA, Yee D. Role of insulin-receptor substrate-1 (IRS-1) in insulin-like growth factor-I (IGF-I) and inteleukin-4 (IL-4) mediated effects in human breast cancer. Under Revision
62. Gooch JL, Christy, BA, Yee D. Stat6 mediates growth inhibition and apoptosis in human breast cancer cells. *Neoplasia*, 4:324-331, 2002
63. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, Osborne CK. FKHR functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. *J Biol Chem* 276:27907-27912., 2001
64. Zhang X, Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. *Cancer Res* 62:4369-4375 2002
65. Bolan PJ, DelaBarre L, Baker EH, Merkle H, Everson LI, Yee D, Garwood M. Eliminating spurious lipid sidebands in 1H spectra of breast lesions. *Magn. Reson. Med.*, 48:215-222, 2002
66. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. *Cancer Res* 62:4491-4498 2002
67. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. *Cancer Res* 63:627-635 2003
68. Zhang X, Cromwell JW, Kunjummen D, Yee D, Garcia-Aquilar J. The alpha2 and alpha 3 integrins are required for morphologic differentiation of an intestinal epithelial cell line. *Surgery* 133:429-437 2003
69. Schmitz KH, Ahmed RL, Yee D. Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women. *Cancer Epidemiol Biomarkers Prev* 11:1597-1604 2002
70. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS. Trastuzumab and IL-2 in HER-2 positive metastatic breast cancer: a pilot study. *Clin Cancer Res* 9:2440-2446 2003.
71. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. In vivo quantification of choline compounds in the breast with <sup>1</sup>H MR spectroscopy. *Magn Resonan Med*, 50:1134-1143 2003

72. De Larco JE, Wuertz BR, Yee D, Rickert BL, Furcht LT. Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. *Proc Natl Acad Sci U S A* 100:13988-13993 2003
73. Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, Sachdev D, Yee D, Brunner N, Ikle D, Fujita-Yamaguchi Y. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. *Horm Metab Res* 35:836-842 2003
74. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor-1 inhibits metastasis of human cancer cells. *J Biol Chem* 279:5017-5024 2004
75. Zhang S, Kamaraju S, Hakuno F, Kabuta T, Takahashi S-I, Sachdev D, Yee D. Motility response to insulin-like growth factor-I in MCF-7 cells is associated with IRS-2 activation and integrin expression. *Breast Canc Res Treat*, 83:161-170 2004.
76. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman D, Manivel JC, Sonenberg N, Yee D, Bitterman P, Polunovsky V. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. *Cancer Cell*, 5:553-563 2004.
77. Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D, Kratzke RA. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. *Cancer Res* 64:7479-7485 2004
78. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo <sup>1</sup>H MR spectroscopy--a pilot study at 4 T. *Radiology* 233:424-431 2004
79. Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le CT, Kelcz F, Lechner MC, Luikens BA, Carlson RA, Brandt KR, Amrami KK, Nelson MT, Everson LI, Emory TH, Tuttle TM, Yee D, Garwood M. Adding in vivo quantitative <sup>1</sup>H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. *Radiology* 236:465-475 2005
80. Zhang X, Lin M, van Golen KL, Yoshioka K, Itoh K, Yee D. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. *Breast Cancer Res Treat* 93:159-168 2005
81. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. *Cancer Epidemiol Biomarkers Prev* 14:1672-1680 2005

82. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. *Cancer Res* 66:2391-2402 2006
83. Kirstein MN, Brundage RC, Elmquist WF, Rimmel RP, Marker PH, Guire DE, Yee D. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. *Breast Cancer Res Treat* 96:217-225 2006
84. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. *Mol Cancer Ther* 5:611-620 2006
85. Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. *Cancer* 106:2076-2083 2006
86. Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. *J Clin Oncol* 24:2765-2772 2006
87. Whitson BA, Jacobson BA, Frizelle S, Patel MR, Yee D, Maddaus MA, Kratzke RA. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. *Ann Thorac Surg* 82:996-1001; discussion 1001-1002 2006
88. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. *Br J Cancer* 95:1220-1228 2006
89. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. *Cancer Res* 67:391-397 2007
90. Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. *Endocrinology* 148:1080-1088 2007
91. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. *Mol Cancer Ther* 6:1-12 2007
92. Kirstein MN, Wieman KM, Williams BW, Fisher JE, Marker PH, Le CT, Yee D, Kratzke RA. Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. *Lung Cancer* 58:196-204 2007
93. Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke RA, Yee D. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. *Cancer Chemother Pharmacol*, 61:291-299 2008

94. Haddadin IS, McIntosh A, Meisamy S, Corum C, Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. *NMR Biomed* 22:65-76 2007
95. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. *J Clin Invest* 118:2609-2619 2008
96. Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. *Breast Cancer Res Treat*, 114:277-285 2009
97. Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. *Mol Cancer Res* 6:1491-1498 2008
98. Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. *NMR Biomed* 22:65-76 2009
99. Corum CA, McIntosh AD, Bolan PJ, Nelson M, Snyder AL, Powell NJ, Boyum J, Emory TH, Yee D, Tuttle TM, Everson LI, Garwood M. Feasibility of single-voxel MRS measurement of apparent diffusion coefficient of water in breast tumors. *Magn Reson Med* 61:1232-1237 2009
100. Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. *Clin Cancer Res* 15:2840-2849 2009
101. Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D. Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. *Br J Cancer* 101:71-79 2009. PMID:19491901
102. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. *Oncogene* 29:251-262, 2010 PMID:19838209
103. Blaes AH, Gaillard P, Peterson BA, Yee D, Virnig B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. *Breast Cancer Res Treat* 122:585-590 2010. PMID:20058065.
104. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. *Oncogene* 29:2517-2527 2010. PMID:20154728.

105. Hui SK, Khalil A, Zhang Y, Coghill K, Le C, Dusenbery K, Froelich J, Yee D, Downs L. Longitudinal assessment of bone loss from diagnostic computed tomography scans in gynecologic cancer patients treated with chemotherapy and radiation. *Am J Obstet Gynecol* 203:353 e351-357 2010. PMID:20684943.
106. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. *Mol Endocrinol* 25:516-528 2011. PMID:21292829.
107. Cochrane MR, Cittelly DM, Howe ER, Spoelstra NS, McKinsey EL, LaPara KS, Elias A, Yee D, Richer JK. MicroRNAs link estrogen receptor alpha status and dicer levels in breast cancer. *Hormones and Cancer* 1:306-319 2010. PMID:21761362
108. Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. *Endocr Relat Cancer* 18:C19-24 2011. PMID:21613412.
109. Zeng X, Zhang H, Oh A, Zhang Y, Yee D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. *Breast Cancer Res Treat* 133:117-126 2012. PMID:21850397.
110. Potter DA, Yee D, Guo Z, Rodriguez M. Should diabetic women with breast cancer have their own intervention studies? *Endocr Relat Cancer* 19:C13-17 2012. PMID:22180498.
111. Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors. *Cancer* 118:2004-2013 2012. PMID:21952948.
112. Hui SK, Fairchild GR, Kidder LS, Sharma M, Bhattacharya M, Jackson S, Le C, Yee D. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid. *Calcif Tissue Int* 90:40-49 2012. PMID:22083107.
113. Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN. Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine. *AAPS J* 14:1-9 2012. PMID:22101930. PMC ID: 3291184
114. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? *J Natl Cancer Inst* 104:975-981 2012. PMID:22761272.
115. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment. *Cancer Res* 72:3372-3380 2012. PMID:22573715.
116. Gu D, Turesky RJ, Tao Y, Langouet SA, Nauwelaers GC, Yuan JM, Yee D, Yu MC. DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 4-aminobiphenyl are infrequently detected in human mammary tissue by liquid chromatography/tandem mass spectrometry. *Carcinogenesis* 33:124-130 2012. PMID:2207261. PMC ID:3276332

117. Hui SK, Sharkey L, Kidder LS, Zhang Y, Fairchild G, Coghill K, Xian CJ, Yee D. The influence of therapeutic radiation on the patterns of bone marrow in ovary-intact and ovariectomized mice. *PLoS One* 7:e42668 2012. PMID:22880075. PMC ID: 3412808
118. Hui SK, Fairchild GR, Kidder LS, Sharma M, Bhattacharya M, Jackson S, Le C, Petryk A, Islam MS, Yee D. The influence of therapeutic radiation on the patterns of bone remodeling in ovary-intact and ovariectomized mice. *Calcif Tissue Int* 92:372-384 2013. PMID:23314741. PMC ID: 3595353
119. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. APOBEC3b is an enzymatic source of mutation in breast cancer. *Nature* 494:366-370 2013. PMID:23389445.
120. Bolan PJ, Arentsen L, Sueblinvong T, Zhang Y, Moeller S, Carter JS, Downs LS, Ghebre R, Yee D, Froelich J, Hui S. Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. *J Magn Reson Imaging* 2013. PMID:23450703. PMC ID: 3690168
121. Forsman CL, Ng BC, Heinze RK, Kuo C, Sergi C, Gopalakrishnan R, Yee D, Graf D, Schwertfeger KL, Petryk A. Bmp-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization. *Dev Biol* 373:95-106 2013. PMID:23103586. PMC ID: 3508155
122. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Puztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. *Clin Cancer Res* 19:2817-2823 2013. PMID:23470967.
123. Zhang X, Diaz MR, Yee D. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. *Breast Cancer Res Treat* 139:351-360 2013. PMID:23686416. PMC ID: 3711713
124. Xu W, Banerji S, Davie JR, Kassie F, Yee D, Kratzke R. Yin yang gene expression ratio signature for lung cancer prognosis. *PLoS One* 8:e68742 2013. PMID:23874744. PMC ID: 3714286
125. Yang Y, Yee D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. *Cancer Res* 74:2295-2305 2014. PMID:24686172. PMC ID: 4006361
126. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. *Oncogene* 34:506-515 2015. PMID:24469035. PMC ID:4112172



127. Yagi M, Arentsen L, Shanley RM, Rosen CJ, Kidder LS, Sharkey LC, Yee D, Koizumi M, Ogawa K, Hui SK. A dual-radioisotope hybrid whole-body micro-positron emission tomography/computed tomography system reveals functional heterogeneity and early local and systemic changes following targeted radiation to the murine caudal skeleton. *Calcif Tissue Int* 94:544-552 2014. PMID:24562595. PMC ID: 3987955
128. Arentsen L, Yagi M, Takahashi Y, Bolan PJ, White M, Yee D, Hui S. Validation of marrow fat assessment using noninvasive imaging with histologic examination of human bone samples. *Bone* 72:118-122 2015. PMID:25460181. PMC ID:4282942
129. Hui SK, Arentsen L, Sueblinvong T, Brown K, Bolan P, Ghebre RG, Downs L, Shanley R, Hansen KE, Minenko AG, Takhashi Y, Yagi M, Zhang Y, Geller M, Reynolds M, Lee CK, Blaes AH, Allen S, Zobel BB, Le C, Froelich J, Rosen C, Yee D. A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. *Bone* 73:90-97 2015. PMID:25536285. PMC ID:4336831
130. Hui SK, Arentsen L, Wilcox A, Shanley R, Yee D, Ghebre R. Spatial and temporal fracture pattern in breast and gynecologic cancer survivors. *J Cancer* 6:66-69 2015. PMID:25553090. PMC ID:4278916
131. Avdulov S, Herrera J, Smith K, Peterson M, Gomez-Garcia JR, Beadnell TC, Schwertfeger KL, Benyumov AO, Manivel JC, Li S, Bielinsky AK, Yee D, Bitterman PB, Polunovsky VA. eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells. *Cancer Res* 75:687-697 2015. PMID:25524901. PMC ID:4333007
132. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. *Clin Cancer Res* 21:2911-2915 2015. PMID:25712686. PMC ID: PMC4490043
133. Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS, Zhou X. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. *PLoS One* 10:e0133152 2015. PMID:26173023. PMC ID:PMC4501840
134. Samavat H, Dostal AM, Wang R, Bedell S, Emory TH, Ursin G, Torkelson CJ, Gross MD, Le CT, Yu MC, Yang CS, Yee D, Wu AH, Yuan JM, Kurzer MS. The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant

- characteristics. *Cancer Causes Control* 26:1405-1419 2015. PMID:26206423. PMC ID:PMC4567901
135. Blaes A, Duprez D, Defor T, Shanley R, Beckwith H, Haddad T, Potter D, Yee D, Sanghavi K, Jacobson P. Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. *Springerplus* 4:32 2015. PMID:25646154. PMC ID:PMC4309801
  136. Blaes AH, Rehman A, Vock DM, Luo X, Menge M, Yee D, Missov E, Duprez D. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. *Vasc Health Risk Manag* 11:591-594 2015. PMID:26648730. PMC ID: PMC46645311.
  137. Walter W, Thomalla J, Bruhn J, Fagan DH, Zehowski C, Yee D, Skildum A. Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. *Springerplus* 4:689 2015. PMID:26576332. PMC ID: PMC46411421.
  138. Yagi M, Froelich J, Arentsen L, Shanley R, Ghebre R, Yee D, Hui S. Longitudinal FDG-PET Revealed Regional Functional Heterogeneity of Bone Marrow, Site-Dependent Response to Treatment and Correlation with Hematological Parameters. *J Cancer* 6:531-537 2015. PMID:26000044. PMC ID: PMC4439938
  139. Ochnik AM, Peterson MS, Avdulov SV, Oh AS, Bitterman PB, Yee D. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. *Neoplasia* 18:100-110 2016. PMID:26936396. PMC ID: PMC5005264
  140. Chan JY, LaPara K, Yee D. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. *Oncogene* 2016. PMID:26876199. PMC ID: pending
  141. Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. *PLoS One* 11:e0150564 2016. PMID:26991655. PMC ID: PMC4798554
  142. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Puztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, Investigators IS. Adaptive Randomization of Neratinib in Early Breast Cancer. *N Engl J Med* 375:11-22 2016. PMID:27406346. PMC ID: PMC5259558
  143. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Puztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley

- BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, Investigators IS. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. *N Engl J Med* 375:23-34 2016. PMID:27406347. PMC ID: PMC5259561
144. Zelenko Z, Gallagher EJ, Antoniou IM, Sachdev D, Nayak A, Yee D, LeRoith D. EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. *Endocr Relat Cancer* 23:747-758 2016. PMID:27435064. PMC ID: PMC4990486
145. Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, Span PN, Foekens JA, Martens JW, Yee D, Harris RS. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. *Sci Adv* 2:e1601737 2016. PMID:27730215. PMC ID: PMC5055383
146. Arentsen L, Hansen KE, Yagi M, Takahashi Y, Shanley R, McArthur A, Bolan P, Magome T, Yee D, Froelich J, Hui SK. Use of dual-energy computed tomography to measure skeletal-wide marrow composition and cancellous bone mineral density. *J Bone Miner Metab* 35:428-436 2017. PMID:27942979. PMC ID: PMC5689468
147. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM, Investigators ATtI-. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. *J Magn Reson Imaging* 46:290-302 2017. PMID:27981651. PMC ID: PMC5464996
148. Kruziki MA, Case BA, Chan JY, Zudock EJ, Woldring DR, Yee D, Hackel BJ. <sup>64</sup>Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor. *Mol Pharm* 13:3747-3755 2016. PMID:27696863. PMC ID: pending
149. Chan JY, Hackel BJ, Yee D. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds. *Mol Cancer Ther* 16:1324-1334 2017. PMID:28468775. PMC ID: PMC5518922
150. Fagan DH, Fettig LM, Avdulov S, Beckwith H, Peterson MS, Ho YY, Wang F, Polunovsky VA, Yee D. Acquired tamoxifen resistance in MCF-7 breast cancer cells requires hyperactivation of eIF4F-mediated translation. *Horm Cancer* 2017. PMID:28577281. PMC ID: PMC5518927
151. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppe JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. *Breast Cancer Res* 19:107 2017. PMID:28893315. PMC ID: PMC5594551

152. Lee H, Ghebre R, Le C, Jang YJ, Sharratt M, Yee D. Mobile Phone Multilevel and Multimedia Messaging Intervention for Breast Cancer Screening: Pilot Randomized Controlled Trial. *JMIR Mhealth Uhealth* 5:e154 2017. PMID:29113961. PMC ID: PMC5698632
153. Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, Yee D, Vogel R, Luepker R, Duprez D. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. *Breast Cancer Res Treat* 166:541-547 2017. PMID:28801846. PMC ID: pending
154. Samavat H, Ursin G, Emory TH, Lee E, Wang R, Torkelson CJ, Dostal AM, Swenson K, Le CT, Yang CS, Yu MC, Yee D, Wu AH, Yuan JM, Kurzer MS. A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer. *Cancer Prev Res (Phila)* 2017. PMID:28904061. PMC ID: pending
155. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. *NPJ Breast Cancer* 3:31 2017. PMID:28948212. PMC ID: PMC5572474
156. Yang Y, Chan JY, Temiz NA, Yee D. Insulin Receptor Substrate Suppression by the Tyrophostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. *Horm Cancer* 2018. PMID:30229539. PMC ID: Pending

## Book Chapters and Reviews

1. Dickson RB, Bates SE, Valverius E, Knabbe C, Salomon D, Freter C, Huff KK, Bronzert D, Walker-Jones D, Favoni R, Yee D, Zugmaier G, Ennis B, Clarke R, Kern F, Rosen N, Lippman ME. Estrogen and antiestrogen regulation of mitogenic growth factors in human breast cancer cells. 3rd Int Congress on Hormones and Cancer, Hamburg, Germany, Raven Press, 1988.
2. Yee D, Lippman ME. Growth regulation of breast cancer. In High Risk Breast Cancer, Ragasz J and Ariel A (eds), Springer-Verlag, Berlin, pp 315-342, 1989.
3. Yee D, Cullen KJ, Paik S, Lippman ME, Rosen N. Growth regulation of human breast cancer by insulin-like growth factors. In Molecular and Cellular Aspects of IGF-I, LeRoith D and Raizada M (eds), Plenum Press, New York, 1989.
4. Yee D, Favoni RE, Rosen N, Cullen KJ. The insulin-like growth factors, their receptors and their binding proteins in human breast cancer. In Regulatory Mechanisms in Breast Cancer, Lippman ME and Dickson RB (eds), Kluwer Academic Publishers, Boston, pp 93-106, 1991.
5. Rosen N, Yee D, Lippman ME, Paik S, Cullen KJ. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 18:S55-S62, 1991.
6. Figueroa JA, Yee D, McGuire WL. Breast Cancer. In Practice of Laboratory Medicine, Rock R, Noe DA (eds), Williams and Wilkins.
7. Krywicki RF and Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Res Treat 22:7-19, 1992.
8. Figueroa JA and Yee D. The insulin-like growth factor binding proteins in human breast cancer. Breast Cancer Res Treat 22:81-90. 1992.
9. Yee D and Von Hoff DD. Molecular biology for the oncologist: In Medical Oncology, Second Edition, Calabresi P and Schein P (eds), McGraw Hill, New York, pp 3-22, 1993.
10. Figueroa JA and Yee D. Insulin-like growth factor binding proteins: Potential inhibitors of cancer cell growth. Drugs of the Future 19:477-483, 1994.
11. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 32:85-95, 1994.
12. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415-421, 1995.
13. Yee D. The insulin-like growth factors and breast cancer—revisited. Breast Cancer Research Treat 47:197-199, 1998.

14. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. *Breast Cancer Res Treat* 47:295-302, 1998.
15. Yee D, Jackson JG, Weng C-N, Gooch JL, Lee AV. The IGF system in breast cancer. In Molecular Mechanisms to Regulate the Activities of Insulin-like Growth Factors (Excerpta Medica International Congress Series 1151), Takano K, Hizuka N, Takahashi S-I (eds), Elsevier Science BV, Amsterdam, 1998, pp 319-325.
16. Lee AV, Yee D. The IGF system in breast cancer cell proliferation and progression. In *Endocrinology of Breast Cancer*, Manni A (ed), Humana Press, Totowa, NJ, 1999, pp 187-204.
17. Yee D, Lee AV. Insulin-like growth factors and endocrine neoplasia. In Contemporary Endocrinology: Endocrine Oncology, Ethier SP (ed), Humana Press, Totowa NJ, 2000, pp. 193-214,
18. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. *J Mammary Gland Biology & Neoplasia*, 5:107-115, 2000.
19. Wood TL, Yee D. IGFs and IGFs in the normal mammary gland and in breast cancer (Editorial). *J Mammary Gland Biol Neoplasia* 5:1-5, 2000
20. Zhang X, Yee D. Insulin-like growth factors and their receptors in breast cancer, *Breast Cancer Res*, 2:170-175, 2000
21. Yee D, Lange CA: Crosstalk between estrogen receptors and growth factor signaling, in Manni A, Verderame MF (eds): *Contemporary Endocrinology: Selective Estrogen Receptor Modulators: Research and Clinical Applications*. Totowa, New Jersey, Humana Press, 2002, pp 77-95
22. Sachdev D, Yee D. The IGF system and breast cancer. *Endocr Relat Cancer* 8:197-209. 2001
23. Yee D, Kiang DT. Hormonal Agents. In Current Cancer Therapeutics, Fourth Edition Kirkwood JN, Lotze MT (ed), Current Medicine, Philadelphia PA, pp. 76-94, 2001
24. Yee D. Are the insulin-like growth factors relevant to cancer? *Growth Horm IGF Res* 11:339-345. 2001
25. Gross JM, Yee D. How does the estrogen receptor work? *Breast Cancer Res*, 4:62-64, 2002
26. Yee D. The insulin-like growth factor system as a treatment target in breast cancer. *Semin Oncol* 29:86-95 2002
27. Gross JM, Yee D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. *Cancer Metastasis Review* 22:327-336, 2003

28. Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. *Semin Oncol* 30:125-132 2003
29. Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell DL. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. *Clin Cancer Res* 9:516S-523S 2003
30. Yee D. Big babies and breast cancer. *Heme/Onc Today* 4:5-12, 2003
31. Zhang X and Yee D. The type I IGF receptor as a target for breast cancer therapy *Breast Disease* 17:115-124, 2003.
32. Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. *Growth Horm IGF Res* 14:261-269 2004
33. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. *Expert Opin Investig Drugs* 13:1569-1577 2004
34. Tuttle TM, Yee D. Bilateral Breast Cancer in Advanced Therapy of Breast Disease Singletary E, Robb GL, and Hortobagyi GN (eds), BC Decker, Hamilton pp. 629-638, 2004
35. Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. *Clinical Cancer Res* 11:944s-950s 2005
36. Garwood M, McIntosh A, Bolan PJ, Meisamy S, Snyder CJ, Stycznski A, DelaBarre L, Ellerman J, Gulbahce E, Tuttle T, Everson LI, Emory TH, Nelson MT, Yee D, Vaughan JT. Clinical Assessment of Breast Cancer Using 1H MRS at High Magnetic Field. In Jagannathan NR: *Biomedical Magnetic Resonance: Proceedings of the International Workshop*, New Delhi, Jaypee Brothers, 2005
37. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: Magnetic resonance spectroscopy. *Breast Cancer Res* 7:149-152 2005
38. Kirstein MN, Yee D. Commentary on a phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. *Am J Oncol Rev* 4:595-598 2005
39. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. *Cancer Res* 65:10123-10127 2005
40. Haddad T, Yee D. Targeting the insulin-like growth factor axis as a cancer therapy. *Future Oncol*, 2:101-110 2006
41. Yee D. Targeting insulin-like growth factor pathways. *Br J Cancer* 94:465-468 2006

42. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. *J Mammary Gland Biol Neoplasia* 11:27-39 2006
43. Zhang H, Yee D. Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? *Clin Cancer Res* 12:6323-6325 2006
44. Zeng X, Yee D. Insulin-like growth factors and breast cancer therapy. In: Yu D, Hung MC, eds. *Breast Cancer Chemosensitivity*. Vol. 608. Austin: Landes Bioscience and Springer Science+Buisness Media, LLC; 2007:101-112.
45. Zeng X, Yee D. Insulin-like growth factors and breast cancer therapy. *Adv Exp Med Biol* 608:101-112 2007
46. Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. *Nanomedicine* 3:83-91 2008
47. Haddad TC, Yee D. Of mice and (wo)men: is this any way to test a new drug? *J Clin Oncol* 26:830-832 2008
48. Lange CA, Yee D. Progesterone and breast cancer. *Womens Health (Lond Engl)* 4:151-162 2008
49. Yee D, Wood TL. The IGF system in mammary development and breast cancer. Preface. *J Mammary Gland Biol Neoplasia* 13:351-352 2008
50. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. *J Mammary Gland Biol Neoplasia* 13:423-429 2008
51. Yee, D. and Potter, D. Steroid Receptors in Breast Cancer. In: K. I. Bland and E. M. Copeland (eds.), *The Breast, Comprehensive Management of Benign and Malignant Diseases*, 4th edition, Vol. 1, pp. 485-497. Philadelphia, PA: Saunders Elsevier, 2009.
52. Yee D. Targeting the insulin-like growth factor receptor. *Clin Adv Hematol Oncol* 7:452-454 2009. PMID:19701152
53. Yee D. Adaptor proteins as targets for cancer prevention. *Cancer Prev Res (Phila Pa)* 3:263-265 2010. PMID:20179300.
54. Yee D. How to train your biomarker. *Clin Cancer Res* 16:3091-3093 2010. PMID:20530694.
55. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. *Diabetes Care* 33:1674-1685 2010. PMID:20587728.



56. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. *CA Cancer J Clin* 60:207-221 2010. PMID:20554718.
57. Zhang H, Uselman RR, Yee D. Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives. *Expert Opin Med Diagn* 5:241-251 2011. PMID:21566703.
58. Haddad, T., and D. Yee. 2011. Basic Principles of Antineoplastic Therapy. In *Breast Surgical Techniques and Interdisciplinary Management*, eds. F.M. Dirbas, and C.E.H. Scott-Conner, 707-715. New York: Springer.
59. Lee AV, Yee D. Targeting IGF-1R: at a crossroad. *Oncology (Williston Park)* 25:535-536; discussion 551 2011. PMID:21717908.
60. Ochnik AM, Yee D. Estrogen-related receptor alpha: an orphan finds a family. *Breast Cancer Res* 14:309 2012. PMID:22574877. PMC ID: 3446323
61. Potter DA, Yee D, Guo Z, Rodriguez M. Should diabetic women with breast cancer have their own intervention studies? *Endocr Relat Cancer* 19:C13-17 2012. PMID:22180498.
62. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. *J Mammary Gland Biol Neoplasia* 2012. PMID:23054135.
63. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytton N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Puztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: A model to safely tailor care while accelerating drug development. *J Clin Oncol* 30:4584-4586; author reply 4588-4589 2012. PMID:23169510.
64. Beckwith H, Yee D. Utilizing RNA-Seq to define phytochemical-induced alterations in insulin and IGF-regulated transcriptomes. In: Bode AM, Dong Z, editors. *Cancer Prevention: Dietary Factors and Pharmacology*. New York: Springer; 2014. p. 189-204.
65. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline. *J Clin Oncol* 32:3307-3329 2014. PMID:25185096.
66. Yee D. A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. *Clin Cancer Res* 21:667-669 2015. PMID:25303978.

67. Beckwith H, Yee D. Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy. *Endocr Pract* 20:1214-1221 2014. PMID:25297664.
68. Yee D. CCR 20th Anniversary commentary: stayin' alive-antiapoptotic proteins and breast cancer. *Clin Cancer Res* 21:665-666 2015. PMID:25691771. PMC ID:4333724
69. Beckwith H, Yee D. Minireview: Were the IGF Signaling Inhibitors All Bad? *Mol Endocrinol* 29:1549-1557 2015. PMID:26366975.
70. Schwerkoske JP, Yee D. New ways to improve breast cancer targeting specific molecular pathways. *Current Cancer Therapy Reviews*, *in press*
71. Yee D, IGF1-R, Cancer Therapeutic Target, Marshall JL (ed.), *in press*
72. Yee D, IGF-1 and IGF-2, Cancer Therapeutic Target, Marshall JL (ed.), *in press*
73. Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast cancer target. *NPJ Precis Oncol* 1:2017. PMID:29152592. PMC ID: PMC5687252
74. DeMichele A, Yee D, Esserman L. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. *N Engl J Med* 377:2287-2289 2017. PMID:29211674. PMC ID: Pending
75. Yee D. Anti-insulin-like growth factor therapy in breast cancer. *J Mol Endocrinol* 61:T61-T68 2018. PMID:29378771. PMC ID:

## Invited Seminars last 6 years

### 2012

Breast Cancer Think Tank 22 – Puerto Morales, Mexico

Oregon Health Sciences University – “Lessons learned from targeting insulin-like growth factor signaling in breast cancer”. Cancer Center grand rounds, Portland, OR

Rush University Cancer Center – “Targeting insulin-like growth factor signaling”, Hematology/Oncology grand rounds, Chicago, IL

American Society of Clinical Oncology Annual Meeting – “Tumor Biology Discussant”, Chicago, IL

Molecular Therapeutics of Cancer Research Conference – “Targeting the IGF receptor and the role of endocrine feedback”, Princeton, NJ

11<sup>th</sup> International Congress on The Future of Breast Cancer – “mRNA translational control in breast cancer”, San Diego, CA

10<sup>th</sup> International Congress on Targeted Therapies in Cancer – “What Does The Future Hold For IGF-1R Inhibitors?”, Washington, DC

Endocrine Society Annual Meeting – “Targeting IGF and insulin signaling in cancer”, Houston, TX

CTRC-AACR San Antonio Breast Cancer Symposium – “Discoveries in translational breast cancer research in 2012”, San Antonio, TX

### 2013

Breast Cancer Think Tank 23 – Punta Cana, Dominican Republic

AACR Annual Meeting Educational Session – “Targeting growth factor signaling pathways in endocrine resistant breast cancer”, Washington, DC

Minnesota Cancer Alliance – 2013 Cancer Disparities Summit

Advances in Breast Cancer Research, AACR symposium – “Targeting downstream effectors of growth factor signaling”, San Diego, CA

Sixth Annual Robert Dickson Memorial Lecture, “A Brief History of the IGF Receptor as a Target in Cancer”. Lombardi Comprehensive Cancer Center, Washington, DC

Veterinary Cancer Society Annual Conference – Keynote Speaker, “Targeting Growth Factors as Cancer Therapy”, Minneapolis, MN

AACR San Antonio Breast Cancer Symposium – Educational session, “Targeting Cell Signaling in Breast Cancer”

### 2014

Breast Cancer Think Tank 24 – Bonaire

Physiology Seminar – “Should Insulin and IGF Signaling Be Targeted In Breast Cancer?”

Michigan State University, East Lansing, MI

Expedition Inspiration, Laura Evans Symposium – Invited Speaker, “Targeting Growth Factor Inputs To Estrogen Receptor, Sun Valley, ID

Chang Gung University Medical School – Visiting Professor, “Should Insulin and IGF Signaling Be Targeted In Breast Cancer?”, Taipei, Taiwan

Breast Cancer of Taiwan Symposium - “Advances in Treatment of HER2+ Breast Cancer”, Taipei, Taiwan

Breast Cancer of Taiwan Symposium - "Cancer Targets and Clinical Trial Designs", Taipei, Taiwan  
7<sup>th</sup> General Assembly and International Conference of Asian Pacific Organization for Cancer Prevention – Invited Speaker, "Will Advances In Breast Cancer Therapy Lead To New Strategies For Prevention?" Taipei, Taiwan  
M.D. Anderson Cancer Center – Invited Speaker, Department of Molecular and Cellular Oncology, "Therapeutic Misadventures in Targeting the IGF-I Receptor", Houston, TX  
American Association of Clinical Endocrinology Annual Meeting – Plenary Speaker, "Breast Cancer and Endocrinology: Where Are We In 2014?", Las Vegas, NV  
Endocrine Society Annual Meeting – Symposium speaker, "Targeting Growth Factor Signaling In Endocrine Sensitive and Resistant Breast Cancer", Chicago, IL  
Rutgers University – Keynote Speaker, Pioneers in Endocrinology workshop, "Is It Possible To Target Insulin-like Growth Factor Signaling in Breast Cancer?" New Brunswick, NJ  
The 5<sup>th</sup> China-USA Forum on Frontiers of Cancer Research – Invited Speaker, "New Breast Cancer Therapies and the Potential For Prevention". Zhengzhou, China

## 2015

Breast Cancer Think Tank 25 – Invited Speaker, "Targeting IRS-1 to Inhibit Breast Cancer". Georgetown, Cayman Islands  
IGF and Insulin in Health and Disease Gordon Conference – Invited Speaker, "Have We Learned Anything by Targeting IGF-IR in Cancer?" Ventura, CA  
University of Wisconsin Molecular and Cellular Pharmacology seminar – Invited Speaker, "Is It Possible To Target IGF Signaling In Breast Cancer?" Madison, WI  
Great Lakes Breast Cancer Symposium – Keynote Speaker, "Lessons Learned From Targeting the IGF Receptor". Cleveland, OH  
14<sup>th</sup> Annual Conference on the Future of Breast Cancer – Invited Speaker, "Neo/Adjuvant HER2 Directed Therapy Management". Huntington Beach, CA.  
Minnesota Breast Imaging Review Course 2015 – Invited Speaker, "Using Breast Imaging to Predict Response To Neoadjuvant Therapy". Minneapolis, MN  
Breast Cancer Educational Association – Invited Speaker, "Progress in Clinical Trials". Minneapolis, MN  
The 6<sup>th</sup> China-US Forum on Frontiers of Cancer Research – Invited Speaker, "Accelerating Drug Development in Breast Cancer Through Neoadjuvant Therapy", Zhengzhou, China  
San Antonio Breast Cancer Symposium – Invited Speaker, "Educational Session: Insulin/IGF Signaling in Breast Cancer", San Antonio, TX

## 2016

Breast Cancer Think Tank 26 – Invited speaker, "Interaction between IRS signaling and ER function". St. Kitts  
Seminar speaker, Texas Tech University Health Sciences Center at El Paso, Department of Biomedical Sciences, Invited speaker, "Targeting signaling pathways in cancer: breast cancer as a model system". El Paso, TX  
Seminar speaker, Georgia Regents University, "Targeting Signaling Pathways In Breast Cancer". Augusta, GA

Invited Speaker, 7<sup>th</sup> China-US Forum on Frontiers of Cancer Research, Hormel Institute,  
“Targeting Endocrine Resistant Breast Cancer”

Invited Speaker, 8<sup>th</sup> International Congress of the GRS-IGF Society, Tel Aviv, Israel, “Targeting  
insulin receptor in breast cancer”

## 2017

Invited speaker, Breast Cancer Think Tank 27 – “Targeting Insulin Receptor”. St. Lucia

Keynote Speaker, Thriving Together: the Annual Conference on Metastatic Breast Cancer –  
“Metastatic Breast Cancer: A Medical and Research Update” and “Hope on the Horizon:  
Immunotherapy”. Philadelphia, PA

Invited Speaker, Innovations in the Management of Cancer Conference: A Focus on Breast –  
“Drug Development in Early Stage Breast Cancer: The I-SPY2 Experience”. Sioux Fall, SD

Invited Speaker, The 5<sup>th</sup> Annual Hormel Institute International Cancer Research Conference –  
“Disruption of insulin receptor function in breast cancer”. Austin, MN

Invited Speaker, 16<sup>th</sup> Annual International Congress on the Future of Breast Cancer, “PI3K and  
other Emerging Targets for ER+ Metastatic Breast Cancer”. San Diego, CA

Invited Speaker, Developmental therapeutics: Immuno-Oncology & Beyond seminar. University  
of Kansas. “Neoadjuvant therapy of breast cancer as a model for drug development: The I-  
SPY 2 experience.

Keynote Speaker, Midwest Metastatic Breast Cancer Conference. “Historical overview and  
evolution of metastatic breast cancer”. Minneapolis, MN

Invited Speaker, 3M Breast Cancer Awareness Day, “Progress in Breast Cancer”, St. Paul MN

## 2018

Invited Speaker, Breast Cancer Think Tank 28 – “Should pCR be the goal in neoadjuvant  
therapy?”. Curacao

Invited Speaker, Cancer Biology Training Grant, University of Colorado Graduate School – “What  
we learned about IGF signaling in breast cancer”. Aurora, CO

Invited Speaker, Southeastern Wisconsin Cancer Conference - “Systemic therapy for advanced  
disease”, Milwaukee, WI

Invited Speaker, UC San Francisco Breast Oncology Program – “What we learned from I-SPY 2  
and What’s Next?” San Francisco, CA

Invited Speaker, Hennepin County Medical Center Grand Rounds – “Changing Breast Cancer  
Outcomes By Changing When Chemotherapy Is Given”, Minneapolis, MN

Invited Speaker, 17<sup>th</sup> International Conference on the Future of Breast Cancer East and West–  
“Neoadjuvant and Adjuvant Therapy Considerations For TNBC”, San Diego, CA and New  
York, NY

Invited Speaker, First Annual Cancer Disparities Symposium: A Focus on the Burden of Triple-  
Negative Breast Cancer – “Many Tumor Types, Many Outcomes: Novel Concepts in the  
Neoadjuvant/Adjuvant treatments for TNBC”, Milwaukee, WI

Invited Speaker, 5<sup>th</sup> Annual Colegio Mexicano Para La Investigacion Del Cancer – “Precision  
Medicine in Early Stage Breast Cancer: The Case For Neoadjuvant Therapy”, Puebla, Mexico

## Other Support

### Active

**P30 CA 077598 (Yee)** 06/01/98 - 01/31/19  
 NIH/NCI \$2,711,113 6.00 calendar  
 Cancer Center Support Grant – Director  
 This grant provides infrastructure for cancer research, education and patient care for the citizens of the Minnesota and the surrounding region.

**P01 CA210961-01A1 (P.I. L. Esserman, Proj 4 Leader Yee)** 07/01/2017-06/30/2022  
 NIH/NCI \$1,694,810 0.6 calendar  
 I-SPY2+: Evolving the I-SPY2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer  
 This project will allow patients enrolled on the I-SPY2 trial to receive additional therapy based on the molecular subtype of their cancer. Dr. Yee serves at the leader of project 4 which is entitled “Develop a portfolio of agents for switching that match biology of residual tumor burden”.

**R43 CA224412-02 (P.I. Skinner, Co-I Yee)** 08/22/2018-07/31/2019  
 NIH/NCI \$224,098 0.24 calendar  
 Physical Activity Platform to Improve Bone Health in Cancer Survivors  
 This project will test a smartphone app (Thrivors+BH™) as a novel tool to bridge the gaps between cancer survivorship, physical activity, value-based care and health care organizations (providers and payers), to positively impact bone health in breast cancer survivors.

### Completed

**SAC110039 (P.I. Yee)** 07/01/2010-03/31/2018  
 Komen for the Cure \$275,000 0.6 calendar  
 Identifying Translational Regulated Genes Activated By Insulin-like Growth Factor Signaling  
 This project will evaluate the “translatome” downstream of the type I IGF receptor and its adaptor proteins in breast cancer model systems.

**R01 CA074285-11A1 (PI: Yee)** 01/01/98-03/31/13  
 NIH/NCI \$236,362 2.4 calendar  
 Targeting the IGF system in breast cancer

This study will target the IGF system in breast cancer. The research will examine IGF signaling pathways, examine the role of the insulin receptor in breast cancer growth and evaluate mechanisms of resistance to anti-IGF receptor strategies.

**5P50CA116201 (P.I. Ingle, Co-project leader Yee)** 09/21/2011-08/31/2015  
 NIH/NCI \$127,672 0.6 calendar  
 Mayo Clinic Breast Cancer SPORE  
 In this renewal application, Dr. Yee collaborated with Dr. Paul Haluska in Project #3, “Regulation of Hormone Resistant Breast Cancer by IGF and Insulin System Signaling”. The goal of this project is to develop anti-IGF therapies to prevent and overcome resistance to anti-estrogen therapies.

**Translational Grant T2012-010 (PI: Harris Co-PI: Yee)** 11/01/12-10/31/2015  
 V Foundation \$181,818 0.12 calendar  
 Enzyme Catalyzed Mutation in Breast Cancer  
 This proposal evaluates the role of APOBEC3B in endocrine resistant breast cancer.